Like automobiles, ribosomes must pass through 'quality control' after their many components are assembled. Scientists investigated an important component in this control process. The researchers demonstrated that a specific protein, which occurs in all cells from yeast to humans, works like a molecular control switch and prevents incomplete ribosomes from leaving the 'assembly hall'.
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Spider silk fibers are very light, extremely tough and highly stretchable. This makes them interest-ing for industrial applications. Researchers at the Biocenter of the University of Würzburg have now discovered new details about the proteins of which spider silk consists.
A polymer originally designed to help mend broken bones could be successful in delivering chemotherapy drugs directly to the brains of patients suffering from brain tumours, researchers at The University of Nottingham have discovered.
There have recently been several advancements in the world of biomaterial design and tissue validation thanks to the BIODESIGN consortium. Currently, a partnership of 19 research and clinical teams from academic centres, small biotech and large pharmaceutical companies is designing and developing state-of-the-art therapeutic approaches, with the aim to help treat traumatic damage and degenerative diseases in humans and alleviate patient suffering.
Tricking algae's biological clock to remain in its daytime setting can dramatically boost the amount of valuable compounds that these simple marine plants can produce when they are grown in constant light.
Designing new drugs based on the body's own molecules will be the focus of a new Center for Biopharmaceuticals that was launched at the Faculty of Health and Medical Sciences on 1 November. The Center will help solve the pharmaceutical challenges of the future in the field of biological drugs.
Entrepreneurial scientists in the synthetic biology space can benefit from a new GBP 10M investment fund that opens for business today. The new fund will help companies in the early stages of their journey towards sustainability, through investment, strategic support and leveraging private capital.